NeurogesX Reports First Quarter 20...(obligation to update these forward-looki...)

Date:5/15/2008

obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing of regulatory filings with respect to NeurogesX' product candidates, including for NGX-4010 the potential filing of an NDA and the filing of additional clinical data with respect to NeurogesX' MAA, and for NGX-1998 the filing of an IND; the timing of initiation of clinical development of NGX-1998 and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

Stephen Ghiglieri

Chief Financial Officer

(650) 358-3310

The Ruth Group

Stephanie Carrington / Jared Hoffman (investors)

(646) 536-7017 / 7013

SOURCE NeurogesX, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. NeurogesX to Report First Quarter 2008 Financial Results
2. NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
3. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
4. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
5. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
6. NeurogesX Closes $25 Million Private Placement
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
9. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10. NeurogesX Expands Senior Management Team
11. NeurogesX to Present at UBS 2007 Global Life Sciences Conference